Home › Neoplasms by Histologic Type › California › Los Angeles
Neoplasms by Histologic Type clinical trials in Los Angeles, CA
4 studies for Neoplasms by Histologic Type are looking for participants at sites in and around Los Angeles (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RecruitingPhase 1
- USC Norris Comprehensive Cancer Center, Los Angeles
- UCLA Health - Bowyer Oncology Center, Los Angeles
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RecruitingPhase 1/2
- California Research Institute, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RecruitingPhase 2
- UCLA Department of Medicine, Los Angeles
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Recruiting
- Oncology Institute for Hope and Innovation, Los Angeles
Neoplasms by Histologic Type trials in other cities
- Boston, MA5 studies
- Atlanta, GA5 studies
- Chicago, IL4 studies
- Houston, TX4 studies
- St. Louis, MO3 studies
- Dallas, TX3 studies
- Tampa, FL3 studies
- Baldwin Park, CA3 studies
- Clifton, NJ3 studies
- San Francisco, CA3 studies
- Nashville, TN3 studies
- New York City, NY3 studies
Other studies in Los Angeles
- Non-Small Cell Lung Cancer87 studies
- Cancer (all types)74 studies
- Breast Cancer73 studies
- Prostate Cancer61 studies
- Colorectal Cancer59 studies
- Metastatic Cancer57 studies
- Ovarian Cancer50 studies
- Lung Cancer45 studies
- Head and Neck Squamous Cell Carcinoma42 studies
- Pancreatic Cancer35 studies
- Endometrial Cancer34 studies
- Melanoma34 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.